project id: TCGA-BLCA; case submitter id: TCGA-E7-A4XJ; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.93; rna integrity number: 8.2; age at index: 66; days to birth: -24279; days to death: 68; ethnicity: not hispanic or latino; gender: male; race: asian; vital status: Dead; year of birth: 1946; age at diagnosis: 24279; ajcc clinical t: T2; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 16.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 1.095890410958904; pack years smoked: 20.0; is ffpe: false; composition: Not Reported; days to collection: 82; days to sample procurement: 0; initial weight: 860.0; portion submitter id: TCGA-E7-A4XJ-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 85.0; percent tumor nuclei: 80.0;